Skip to Main Content
Contribute Try STAT+ Today

Rise and shine, everyone, another busy day is on the way. We can tell because the official mascot is itching to bound about the Pharmalot grounds in search of varmint and the official and unofficial to-do lists are growing longer. But what can you do? The world, such as it is, keeps spinning. So to brace ourselves, we are brewing cups of stimulation. Our choice today, for those tracking this sort of thing, is butter pecan, a smooth and aromatic favorite. Meanwhile, we have once again assembled a few items of interest for you in hopes that your journey goes well today. As always, please do keep in touch, and stay safe. …

Moderna (MRNA) predicts that existing Covid-19 vaccines will be less effective against Omicron than they have been against the Delta version, sending global stock markets sharply lower, The Guardian writes. Moderna chief executive officer Stéphane Bancel says while it would take two weeks to get data on how the existing vaccines perform against the new Covid variant – and whether it causes severe disease – it would take several months to tweak the current vaccines to tackle Omicron. “There is no world, I think, where [the effectiveness] is the same level … we had with Delta.” But he warned it would be risky to shift Moderna’s entire production capacity to an Omicron-specific jab.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment